Suchergebnisse - "Märten, Angela"

PubPharm (160)

1

Technical considerations for isolated limb perfusion : A consensus paper

enthalten in: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology | 2024

von Hayes, A. | Coker, D. | Been, L. | +34

2

Efficacy and Safety of the MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer : A Case Series

enthalten in: OncoTargets and therapy | 2024

von Yamamoto, N. | Tolcher, A. | Hafez, N. | +8

3

Brightline-2 : a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors

enthalten in: Future oncology (London, England) | 2024

von Yoo, C. | Lamarca, A. | Choi, H. | +8

4

Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations : A Retrospective International Cohort Study (UpSwinG)

enthalten in: The oncologist | 2022

von Popat, S. | Hsia, T. | Hung, J. | +13

5

Sequential Afatinib and Osimertinib in Asian Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer and Acquired T790M : Combined Analysis of Two Global Non-Interventional Studies

enthalten in: OncoTargets and therapy | 2022

von Miura, S. | Jung, H. | Lee, S. | +8

6

Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations : An Updated Database of 1023 Cases Brief Report

enthalten in: Frontiers in oncology | 2022

von Yang, J. | Schuler, M. | Popat, S. | +7

7

Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M : A global non-interventional study (UpSwinG)

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2021

von Popat, S. | Jung, H. | Lee, S. | +10

8

An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations

enthalten in: BMC cancer | 2021

von Park, K. | Kim, J. | Kim, J. | +7

9

An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations

enthalten in: BMC cancer | 2021

von Park, K. | Kim, J. | Kim, J. | +7

10

Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer : final analysis of the GioTag study

enthalten in: Future oncology (London, England) | 2020

von Hochmair, M. | Morabito, A. | Hao, D. | +7

CommentIn: Future Oncol. 2021 Sep 1;17(25):3285-3290. - PMID 34107727

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[16]